Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Rebecca Voaklander & Ira M Jacobson. (2017) Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C. Expert Review of Gastroenterology & Hepatology 11:9, pages 789-795.
Read now
Read now
Laura Benítez-Gutiérrez, Pablo Barreiro, Pablo Labarga, Carmen de Mendoza, José V. Fernandez-Montero, Ana Arias, José M. Peña & Vicente Soriano. (2016) Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opinion on Pharmacotherapy 17:9, pages 1215-1223.
Read now
Read now
Articles from other publishers (20)
Caroline E Boeke, Clement Adesigbin, Olayinka Adisa, Chukwuemeka Agwuocha, Muhammad-Mujtaba Akanmu, Atiek Anartati, Khin Sanda Aung, Amy Azania, Ruth Bello Nabe, Arief Budiman, Yuhui Chan, Umesh Chawla, Fatchanuraliyah, Oriel Fernandes, Gagandeep Singh Grover, Thandar Su Naing, Dang Ngo, Christian B Ramers, Sean Regan, Siddharth Sindhwani, Gertrudis Tandy, Khin Tint, Kinh Van Nguyen, Magdalena Witschi & Craig McClure. (2022) Patient outcomes in public sector hepatitis C treatment programmes: a retrospective cohort analysis across five low- and middle-income countries. BMJ Open 12:12, pages e062745.
Crossref
Crossref
Saima Mushtaq, Atika Mansoor, Muhammad Umar, Amjad Khan, Saima Siddiqi & Sobia Manzoor. (2020) Direct‐acting antiviral agents in the treatment of chronic hepatitis C—Real‐life experience from clinical practices in Pakistan. Journal of Medical Virology 92:12, pages 3475-3487.
Crossref
Crossref
Miriam Coghlan, Aisling O’Leary, Gail Melanophy, Colm Bergin & Suzanne Norris. (2019) Pharmacist-led pre-treatment assessment, management and outcomes in a Hepatitis C treatment patient cohort. International Journal of Clinical Pharmacy 41:5, pages 1227-1238.
Crossref
Crossref
Daniel Esteban Pino Marín, Pedro Amariles, Jaime Alberto Peláez Alvárez, Gloria Priscilla Alvárez Osorio & Juliana González Ceballos. (2019) Aproximación para establecer y evaluar la relevancia clínica de las interacciones medicamentosas en el tratamiento de pacientes infectados con virus de hepatitis C, revisión estructurada (actualización 2015 – 2017). Revista Colombiana de Gastroenterología 34:2, pages 159-176.
Crossref
Crossref
Valentina Pecoraro, Rita Banzi, Elisabetta Cariani, Johanna Chester, Erica Villa, Roberto D'Amico, Vittorio Bertele'Tommaso Trenti. (2019) New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. Journal of Clinical and Experimental Hepatology 9:4, pages 522-538.
Crossref
Crossref
Gema Lledó, Laura Benítez-Gutiérrez, Ana Arias, Silvia Requena, Valentín Cuervas-Mons & Carmen de Mendoza. (2019) Benefits of hepatitis C cure with antivirals: why test and treat?. Future Microbiology 14:5, pages 425-435.
Crossref
Crossref
Deirdre Sawinski. (2019) ESRD patients coinfected with human immunodeficiency virus and Hepatitis C: Outcomes and management challenges. Seminars in Dialysis 32:2, pages 159-168.
Crossref
Crossref
Isabella Esposito, Sebastián Marciano, Leila Haddad, Omar Galdame, Alejandra Franco, Adrián Gadano, Diego Flichman & Julieta Trinks. (2018) Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection. Viruses 11:1, pages 3.
Crossref
Crossref
Moisés Uriarte-Pinto, Herminia Navarro-Aznarez, Natalia De La Llama-Celis, Piedad Arazo-Garcés, Ana María Martínez-Sapiña & María Reyes Abad-Sazatornil. (2018) Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world. International Journal of Clinical Pharmacy 40:3, pages 608-616.
Crossref
Crossref
Vicente Soriano, José Ramos, Pablo Barreiro & Jose Fernandez-Montero. (2018) AIDS Clinical Research in Spain—Large HIV Population, Geniality of Doctors, and Missing Opportunities. Viruses 10:6, pages 293.
Crossref
Crossref
Rolf Wagner, John T. Randolph, Sachin V. Patel, Lissa Nelson, Mark A. Matulenko, Ryan Keddy, John K. Pratt, Dachun Liu, A. Chris Krueger, Pamela L. Donner, Douglas K. Hutchinson, Charles Flentge, David Betebenner, Todd Rockway, Clarence J. Maring, Teresa I. Ng, Preethi Krishnan, Tami Pilot-Matias, Christine Collins, Neeta Panchal, Thomas Reisch, Tatyana Dekhtyar, Rubina Mondal, DeAnne F. Stolarik, Yi Gao, Wenqing Gao, David A. Beno & Warren M. Kati. (2018) Highlights of the Structure–Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530). Journal of Medicinal Chemistry 61:9, pages 4052-4066.
Crossref
Crossref
Massimo Andreoni, Sergio Babudieri, Savino Bruno, Massimo Colombo, Anna L. Zignego, Vito Di Marco, Giovanni Di Perri, Carlo F. Perno, Massimo Puoti, Gloria Taliani, Erica Villa & Antonio Craxì. (2017) Current and future challenges in HCV: insights from an Italian experts panel. Infection 46:2, pages 147-163.
Crossref
Crossref
HELENE B. BERNSTEIN, JEFFREY C. DUNKELBERG & KIMBERLY K. LESLIE. (2018) Hepatitis C in Pregnancy in the Era of Direct-acting Antiviral Treatment: Potential Benefits of Universal Screening and Antepartum Therapy. Clinical Obstetrics & Gynecology 61:1, pages 146-156.
Crossref
Crossref
Edward R. Cachay, Craig Ballard, Bradford Colwell, Francesca Torriani, Charles Hicks & Wm. Christopher Mathews. (2017) Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment. AIDS Research and Therapy 14:1.
Crossref
Crossref
Ana Arias, Antonio Aguilera, Vicente Soriano, Laura Benítez-Gutiérrez, Gemma Lledó, Daniel Navarro, Ana Treviño, Esteban Otero, José M Peña, Valentín Cuervas-Mons & Carmen de Mendoza. (2016) Rate and Predictors of Treatment Failure to All-Oral HCV Regimens outside Clinical Trials. Antiviral Therapy 22:4, pages 307-312.
Crossref
Crossref
K. Yu. Kokina, A. O. Bueverov, P. O. Bogomolov & M. V. Matsievich. (2017) Predictors of the efficiency of short-term interferon-containing therapy using direct-acting antiviral drugs in patients with chronic hepatitis C virus genotype 1. Terapevticheskii arkhiv 89:12, pages 197.
Crossref
Crossref
Kevin Tin, Eiei Soe & James Park. (2016) Management of Direct-Acting Antiviral Failures in Chronic Hepatitis C Infection. Current Hepatology Reports 15:4, pages 296-306.
Crossref
Crossref
Pablo Barreiro, Pablo Labarga, Carmen de Mendoza, Laura Benítez-Gutiérrez, José V Fernandez-Montero, José M Peña & Vicente Soriano. (2015) High Serum HCV RNA in Chronic Hepatitis C Patients Coinfected with HIV despite Successful Antiretroviral Therapy. Antiviral Therapy 21:6, pages 489-494.
Crossref
Crossref
Edward Cachay & Vicente Soriano. (2016) Is HIV still a special population for the treatment of hepatitis C?. AIDS 30:12, pages 2001-2003.
Crossref
Crossref
José Vicente Fernández-Montero & Vicente Soriano. (2016) SOLAR-2: the sun also rises for cirrhotics. The Lancet Infectious Diseases 16:6, pages 624-625.
Crossref
Crossref